The recent first global approval of abaloparatide has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Abaloparatide (Tymlos™): First Global Approval – bone formation fends off fragility fractures in postmenopausal women with high-risk osteoporosis”
Month: June 2017
Midostaurin (Rydapt®): First Global Approval – Double Trap shots on target for FLT3-mutated AML and Advanced SM
The recent first (double) global approval of midostaurin has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Midostaurin (Rydapt®): First Global Approval – Double Trap shots on target for FLT3-mutated AML and Advanced SM”
AdisInsight Enhancements June 2017
The AdisInsight development team has been busy creating new features and improving existing functionality to create an exceptional user experience for you. Read below to see what we have added this month. Continue reading “AdisInsight Enhancements June 2017”
Brigatinib (ALUNBRIG™): First Global Approval – resistance is futile in the battle against metastatic NSCLC
The recent first global approval of brigatinib has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Brigatinib (ALUNBRIG™): First Global Approval – resistance is futile in the battle against metastatic NSCLC”
Valbenazine (Ingrezza™): First Global Approval – taking back control for patients with Tardive Dyskinesia
The recent first global approval of valbenazine has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Valbenazine (Ingrezza™): First Global Approval – taking back control for patients with Tardive Dyskinesia”
Cerliponase Alfa (Brineura™): First Global Approval – first flicker of hope for families living with CLN2
The recent first global approval of cerliponase alfa has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Cerliponase Alfa (Brineura™): First Global Approval – first flicker of hope for families living with CLN2”
Ocrelizumab (Ocrevus™): First Global Approval – making a B-line to crushing the most aggressive form of MS
The recent first global approval of ocrelixumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Ocrelizumab (Ocrevus™): First Global Approval – making a B-line to crushing the most aggressive form of MS”
Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema
The recent first global approval of dupilumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema”
Live webinar: The EMA’s MLM service and options for integration
Join me for a live webinar and Q&A session in June, when we will find out how organisations are managing integration with EMA’s Medical Literature Monitoring (EMA MLM) service and gaining a better understanding of the limitations.
Continue reading “Live webinar: The EMA’s MLM service and options for integration”